First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer
Annie Bjäreback, Ulrika Estenberg, Antonios Tzortzakakis, Rimma Axelsson, Chunde Li, Renske Altena, Thuy A. Tran, Cecilia Hindorf · 2026
Read First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer by Annie Bjäreback, Ulrika Estenberg, Antonios Tzortzakakis, Rimma Axelsson, Chunde Li, Renske Altena, Thuy A. Tran, Cecilia Hindorf (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13275974.txt.
Description
Annie Bjäreback and co-authors report a 2026 first-in-human study of radiation doses from a cancer imaging tracer. The tracer targets a receptor called GRPR, found in large amounts on many tumors but scarce in healthy organs. Knowing where its radiation lands in the body is required before wider use.
Twelve patients, six women with breast cancer and six men with prostate cancer, received the tracer and had scans at six time points. The pancreas absorbed the highest dose, followed by the bladder wall and the kidneys. More than half the tracer left the body in urine within four hours. A standard injection gave a total body dose the authors describe as low, in line with similar tracers already in use.
Catalog record
| CREATOR | Annie Bjäreback, Ulrika Estenberg, Antonios Tzortzakakis, Rimma Axelsson, Chunde Li, Renske Altena, Thuy A. Tran, Cecilia Hindorf |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28273 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |